Pfizer Inc. $PFE Stock Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,348,709 shares of the biopharmaceutical company’s stock after selling 134,154 shares during the period. Russell Investments Group Ltd. owned 0.09% of Pfizer worth $152,732,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Retirement Wealth Solutions LLC increased its stake in shares of Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 509 shares in the last quarter. Keb Asset Management LLC acquired a new position in Pfizer during the 2nd quarter worth about $26,000. Field & Main Bank acquired a new stake in Pfizer in the 2nd quarter valued at about $27,000. Bullseye Investment Management LLC bought a new position in shares of Pfizer in the second quarter worth about $28,000. Finally, Timbuktu Capital Management LLC bought a new position in shares of Pfizer in the second quarter worth about $29,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on PFE shares. Guggenheim increased their price target on shares of Pfizer from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Citigroup increased their price objective on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. Argus set a $40.00 target price on Pfizer in a research note on Wednesday, November 4th. Scotiabank boosted their target price on Pfizer from $33.00 to $35.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, November 4th. Finally, Cantor Fitzgerald upped their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Six analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $30.32.

View Our Latest Report on PFE

Pfizer Trading Down 0.0%

PFE opened at $28.89 on Monday. The firm has a 50 day simple moving average of $28.80 and a 200 day simple moving average of $26.98. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.10. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $31.44. The company has a market cap of $164.65 billion, a price-to-earnings ratio of 41.27, a price-to-earnings-growth ratio of 1.90 and a beta of 0.31.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The company had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the previous year, the company posted $0.87 EPS. The business’s revenue for the quarter was down .4% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 3.04 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 6.0%. Pfizer’s dividend payout ratio is presently 245.71%.

Pfizer Company Profile

(Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.